参考文献/References:
［1］SMITH H O. Gestational trophoblastic disease epidemiology and trends ［J］. Clinical Obstetrics and Gynecology, 2003, 46(3): 541-556.
［2］NGAN S, SECKL M J. Gestational trophoblastic neoplasia management: an update ［J］. Current Opinion in Oncology, 2007, 19(5): 486-491.
［3］FRIJSTEIN M M, LOK C， VAN TROMMEL N E, et al. Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database ［J］. Gynecologic Oncology, 2019, 152(2): 361-367.
［4］Zong L, Zhang M, Wang W,et al. PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia ［J］. Histopathology，2019，75（3）:421-430.
［5］SHARPE A H, PAUKEN K E. The diverse functions of the PD1 inhibitory pathway ［J］. Nature Reviews Immunology, 2018, 18(3): 153-167.
［6］INAGUMA S, WANG Zeng-feng, LASOTA J, et al. Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1) analysis in 5536 cases revealed consistent expression in trophoblastic tumors ［J］. American Journal of Surgical Pathology, 2016, 40(8): 1133-1142.
［7］GHORANI E, KAUR B, FISHER R A, et al. Pembrolizumab is effective for drugresistant gestational trophoblastic neoplasia［J］. Lancet, 2017, 390(1110): 2343-2345.
［8］HUANG M, PINTO A, CASTILLO R P. Complete serologic response to pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma ［J］. Journal of Clinical Oncology, 2017, 35(27): 3172-3174.
［9］YANG Jun-jun, ZON L, WANG Jing, et al. Epithelioid trophoblastic tumors: treatments, outcomes, and potential therapeutic targets ［J］. Journal of Cancer, 2019, 10(1): 11-19.
［10］KOHORN E I, KACINSKI B M, STANLEY E R. Serum levels of macrophage colony-stimulating factor in trophoblastic disease ［J］. Gynecol Oncology, 2000, 80(3): 383-386.
［11］WORLEY MJ， ELIAS K M, HOROWITZ N S, et al. Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute ［J］. Gynecologic Oncology, 2018, 148(1): 5-11.
［12］TRABOULSI W, SERGENT F, BOUFETTAL H A, et al. Antagonism of EG-VEGF receptors as targeted therapy for choriocarcinoma progression in vitro and in vivo ［J］. Clinical Cancer Research, 2017, 23(22): 7130-7140.
［13］SINGH M, KINDELBERGER D, NAGYMANYOKI Z, et al. Vascular endothelial growth factors and their receptors and regulators in gestational trophoblastic diseases and normal placenta ［J］. JOURNAL OF REPRODUCTIVE MEDICINE, 2012, 57(5/6): 197-203.
［14］MELLO J D, RAMOS C P, MICHELIN O C, et al. Genomic profile in gestational and non-gestational choriocarcinomas ［J］. Placenta, 2017，50（2）: 8-15.
［15］LIM W, PARK S, BAZER F W, et al. Apigenin reduces survival of choriocarcinoma cells by inducing apoptosis via the PI3K/AKT and ERK1/2 MAPK pathways ［J］. Journal of Cellular Physiology, 2016, 231(12): 2690-2699.
［16］Morales-Prieto DM, Ospina-Prieto S, Chaiwangyen W, et al. Intranuclear crosstalk between extracellular regulated kinase1/2 and signal transducer and activator of transcription 3 regulates JEG-3 choriocarcinoma cell invasion and proliferation ［J］. Sci World J，2013：259845.
［17］BRAHMER J R, LACCHETTI C, SCHNEIDER B J, et al. Management of Immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline ［J］. Journal of Clinical Oncology, 2018, 36(17): 1714-1768.
［18］RANPURA V, HAPANI S, WU Shenhong. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis ［J］. JAMA : the Journal of the American Medical Association, 2011, 305(5): 487-494.
［19］HAPANI S, SHER A, CHU D, et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a Meta-Analysis ［J］. Oncology, 2010, 79(1/2): 27-38.
相似文献/References:
[1]王黎明,汪辉*.子宫颈癌的诊疗新技术[J].中国计划生育和妇产科,2019,(10):33.
[2]李霞,王东晖,李玲玲,等.剖宫产瘢痕部位侵蚀性葡萄胎1例并文献复习[J].中国计划生育和妇产科,2020,(8):86.
[3]万丽琴,陈建明.未分化结缔组织病与不良妊娠[J].中国计划生育和妇产科,2021,(7):38.[doi:10.3969/j.issn.1674-4020.2021.07.13]
[J].Chinese Journal of Family Planning & Gynecotokology,2021,(10):38.[doi:10.3969/j.issn.1674-4020.2021.07.13]